22nd Century Group completed the acquisition of GVB Biopharma.

22nd Century Group, an agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, completed the acquisition of GVB Biopharma, a hemp/cannabis company. Financial terms were not disclosed. “We are excited to combine with 22nd Century group, pairing our production and manufacturing capabilities together with the best hemp/cannabis plant science in the world. Since 2017, we have built a loyal customer base and continue to add new, rapidly growing customers as demand in our industry accelerates. We sold more than five billion doses of CBD in 2021, and we look forward to further scaling our business as a part of 22nd Century’s comprehensive platform,” Phillip Swindells, GVB CEO.